Notícias e Atividades da Garuda Therapeutics
Executivos
Veja o organograma con seus 19 executivos principais
Biografias mais buscadas da Garuda Therapeutics
- Avanish Vellanki, President and Chief Executive Officer and Direct...
- Adam Craig, Independent Director
- Laurence Reid, Director
Recentes movimentos de executivos em Garuda Therapeutics
- Avanish Vellanki, ingressou na Companhia como President and Chief Executive Officer and Director (Notícia publicada em 4 de março de 2025).
- Adam Craig antes Interim Chief Executive Officer, agora é Independent Director (Notícia publicada em 4 de março de 2025).
Criar um alerta
para seguir os movimentos de executivos da Garuda Therapeutics.
Biotecnologia
Garuda Therapeutics possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnologia
- Transcarent and Accolade have merged (publicado em 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Garuda Therapeutics
- Garuda Therapeutics Announces the Appointment of Avanish Vellanki as President and Chief Executive Officer
- Garuda Therapeutics Closes $50 Million Series A-1 Financing to Advance Off-the-Shelf Blood Stem Cell Therapies
- Garuda Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Garuda Therapeutics Named “Overall Cell Biology Company of the Year” By BioTech Breakthrough
- Garuda Therapeutics Announces the Appointment of Giorgia Scapin, Ph.D., as Chief Scientific Officer
- Be The Match BioTherapies® To Provide Robust Cell Therapy Infrastructure to Support Garuda Therapeutics’ Potentially Ground-Breaking Off-The-Shelf Cell Therapies
- Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
- Garuda Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
- Garuda Therapeutics Announces Appointment of David DiGiusto, Ph.D., as Chief Technology Officer
- Garuda Therapeutics Announces Appointment of Roger Sawhney, M.D., as Chief Financial Officer
- View more press releases Close
Redes sociais sobre Garuda Therapeutics
- Garuda Therapeutics na Wikipedia, Google News e Yahoo Finance
- Garuda Therapeutics na LinkedIn, Twitter e YouTube
